Last updated on November 2018

Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Osteogenesis Imperfecta
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Adult patients aged 18 years and over with a clinical diagnosis of Osteogenesis Imperfecta (OI)
  • Patients willing and able to consent and comply with the study protocol

Exclusion Criteria:

  • Current or previous treatment with an investigational (non-licensed experimental) drug with effects on bone metabolism
  • Contraindication to teriparatide or zoledronic acid
  • Women of childbearing potential not using highly effective methods of contraception
  • Pregnancy
  • Women that are breastfeeding
  • Age < 18 years

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.